A phase II study of acalabrutinib in combination with R-CHOP for previously untreated transplant-ineligible mantle cell lymphoma patients in Spain (the SOUND-MCL Study)


Por: Niebla, AM, Garcia-Sancho, AM, Garcia, JC, Garcia, EA, Mellen, AC and Sancho, JM

Publicada: 1 dic 2025 Ahead of Print: 1 dic 2025
Resumen:


Filiaciones:
Niebla, AM:
 Hosp Univ Vall Hebron, Vall Hebron Inst Oncol VHIO, Hematol Dept, Barcelona, Spain

Garcia-Sancho, AM:
 Univ Salamanca, Hosp Univ Salamanca, IBSAL, CIBERONC,Hematol Dept, Salamanca, Spain

Garcia, JC:
 AstraZeneca Farmaceut Spain, Med Dept, Madrid, Spain

Garcia, EA:
 AstraZeneca Farmaceut Spain, Med Dept, Madrid, Spain

Mellen, AC:
 AstraZeneca Farmaceut Spain, Med Dept, Madrid, Spain

:
 ICO IJC Badalona Hosp Germans Trias i Pujol, Hematol Dept, Badalona, Spain
ISSN: 00064971





Blood
Editorial
American Society of Hematology, 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA, Estados Unidos America
Tipo de documento: Meeting Abstract
Volumen: 146 Número:
Páginas: 1838-1839
WOS Id: 001659028200039

MÉTRICAS